New research reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Research printed in a major medical journal shows that while overweight individuals frequently drop a large proportion of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"People purchasing such treatments must be aware of the risk of quick rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment weight in about 18 months.
Analyzing Approaches
The study, which looked at dozens of studies involving thousands of patients, compared the effects of these new drugs with other pills.
The team emphasize that people who lose weight through lifestyle changes alone generally have a less rapid creep back—around 100 grams monthly—post-intervention.
The Reason for the Rapid Regain
Nutrition scientists believe the way of the drugs accounts for the heightened weight return.
The injections imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, given the high risk of relapse, the therapy might need to be long-term.
This perspective is reinforced by pharmaceutical companies, who say that the findings "highlight the chronic character of excess weight," similar to managing diseases like hypertension.
User Testimonies
Users who have stopped the jabs describe a sudden return of hunger.
"I experienced a switch flipping and you become extremely hungry," described one woman.
The struggle is worsened if users have not established permanent dietary or behavioural modifications during therapy.
Growing Adoption
Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is greater among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while these medications are powerful tools for shedding pounds, they are not a permanent fix and lasting health benefits hinges on ongoing lifestyle support.
